A 'gamer changer' weight loss injection said to be used by celebrities is going to be made available through the NHS in England, health officials have announced.
The appetite suppressant Wegovy, also known as semaglutide, will be given to people living with obesity after the National Institute for Health and Care Excellence (Nice) gave it the green light on NHS use.
Thousands are expected to be offered the drug which some experts have described as a 'pivotal moment' for the treatment of obesity but others have warned it is not a 'quick fix', the MEN reports. A previous study found that people who are given the drug which comes in the form of a weekly injection saw their weight drop by 12 per cent on average after 68 weeks.
Nice has issued final guidance recommending semaglutide which is made by Novo Nordisk for adults with at least one weight-related condition and a body mass index (BMI) score of at least 35. Weight-related conditions that make obese people eligible include type 2 diabetes, high blood pressure, prediabetes, dyslipidemia (unbalanced or unhealthy cholesterol levels), obstructive sleep apnoea and heart disease.
In some cases, people with a BMI of 30 and over may be able to access the drug which is given via a pen injector. Wegovy will only be prescribed as part of a specialist weight management service involving input from several professionals and for a maximum of two years.
It is to be used alongside a reduced-calorie diet and increased physical activity, Nice said. Patients will inject themselves weekly with the drug which suppresses the appetite through mimicking the hormone glucagon-like peptide-1 (GLP-1) that is released after eating.
This makes people feel full, meaning they will eat less and lose weight. Nausea and diarrhoea were the most common side effects of the drug according to a study published in the New England Journal of Medicine.
However, the side effects were 'typically transient and mild-to-moderate in severity and subsided with time'. The drug will soon be available to NHS patient once the launch of the drug in England is confirmed by manufacturer Novo Nordisk.
The NHS in England is required to implement the Nice recommendations within three months of the product becoming commercially available. Helen Knight, director of medicines evaluation at Nice, said: “For some people losing weight is a real challenge which is why a medicine like semaglutide is a welcome option.
"It won’t be available to everyone. Our committee has made specific recommendations to ensure it remains value for money for the taxpayer, and it can only be used for a maximum of two years.
"We are pleased to finally publish our final guidance on semaglutide which will mean some people will be able to access this much talked about drug on the NHS.” Commenting on the news, Alex Miras, professor of endocrinology at Ulster University, said: “This decision made by Nice is a pivotal moment for the treatment of people living with obesity.
"The weight loss that can be achieved with this safe medication is substantial and likely to lead to the improvement of obesity-related complications in a large number of patients." Prof Nick Finer, honorary clinical professor at the National Centre for Cardiovascular Prevention and Outcomes at UCL, added: “The efficacy of semaglutide is a true game changer for the medical treatment of obesity, a chronic disease that shortens life through its many complications.”
Dr Stephen Lawrence, associate clinical professor at the University of Warwick, said: “When used in accordance with the prescribed guidelines, it promotes weight loss in a safe and effective way for most people. It is important to note, however, that this medication is not a quick fix or a replacement for following a healthy lifestyle, which includes regular physical activity and healthy eating.
However, Charity Beat, the UK's leading charity supporting those affected by eating disorders have raised concerns about the 'dangerous' impact the drug may have on people they work with and support. Tom Quinn, Beat’s director of external affairs, said: "Weight-loss medications like semaglutide can be extremely attractive to people with eating disorders as they appear to provide quick results.
"However, these medications can be very dangerous as they can worsen harmful thoughts and behaviours for those unwell, or contribute to an eating disorder developing for someone who is already vulnerable."
Don't miss the latest news from around Scotland and beyond - Sign up to our daily newsletter here.
